News and Announcements
Nico.lab Fundraising Ahead of IPO for Stroke Treatment Technology
- Published June 12, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Nico.lab’s technology enables the fast and accurate image analysis to allow for quick decisions to be made by Doctors.
- The company is planning to raise funds before their IPO in February 2019.
- The funds they plan on raising will help accelerate the strategy to bring their technology, StrokeViewer, to the market in Australia and Europe.
Nico.lab, established in 2015, is planning to raise funds before their IPO in February 2019. The funds they plan on raising will help accelerate the strategy to bring their technology, StrokeViewer, to the market in Australia and Europe. Their technology aims to reduce the treatment time for stroke patients. It will also fund the development of the AI algorithm required for effective stroke detection over the next 12 months. The IPO Funds in February 2019 will focus on the technology rollout in the United States.
Nico.lab’s technology enables the fast and accurate image analysis to allow for quick decisions to be made by Doctors. It will reduce treatment time from hours to minutes. The technology has all four biomarkers required for accurate stroke detection. Within 3 minutes the StrokeViewer informs doctors with a biomarker report and image they can view on any device. Every hour that doctors can treat a stroke victim, the number of patients who recover without significant complications increase by 15%.
The CE certified technology uses artificial intelligence and machine learning to improve performance continually. Nico.lab has had 15 hospitals in the Netherlands sign up to use the technology. Peak Asset Management, an advisory firm, is planning to raise $2.3m, with the shares priced at 15¢, for Nico.lab before the IPO next year.
About Nico.Lab
Nico.lab’s StrokeViewer® uses AI to reduces time-to-decision for stroke patients to 3 minutes compared to the current manual protocol which can take hours.
StrokeViewer® has been approved for roll-out by 15 hospitals.
The company has an exceptional management team and board, with over €4M and years of research spent to date.
Investors have an opportunity at a compelling €4.5M pre-money valuation, ahead of an ASX listing in 1Q18.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
